Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Cost-Effectiveness of Pembrolizumab With Axitinib as First-Line Treatment for Advanced Renal Cell CarcinomaCurr Med Res Opin 2020 Sep 01;36(9)1507-1517, AG Bensimon, Y Zhong, U Swami, A Briggs, J Young, Y Feng, Y Song, J Signorovitch, O Adejoro, A Chakravarty, M Chen, RF Perini, DM Geynisman
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.